Bibliography
- Disse B, Reichel R, Speck GA, et al. Ba679 Br., a novel anticholinergic bronchodilator. Life Sci 1993;52:537-44
- Takahaski T, Belvisi MG, Patel H, et al. Effect of BA679 Br, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir crit Care Med 1994;150:1640-5
- Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva ™): mechanistical considerations and clinical profiler in obstructive lung disease. Life Sci 1999;64:457-64
- Maesen FVP, Smeets JJ, Costongs MAL, et al. Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-scalation study in COPD. Eur Respir J 1993;6:1031-6
- Dixon WE, Brodie TG. Contributions to the physiology of the lungs. Part I. The bronchial muscles, their innervation, and the action of drugs upon them. J Physiol 1903;29:97-173
- Dixon WE, Ransom F. Broncho-dilator nerves. J Physiol 1912;45:413-28
- Macklin CC. The musculature of the bronchi and lungs. Physiol Rev 1929;9:1-60
- Widdicombe JG. Regulation of tracheobronchial smooth muscle. Physiol Rev 1963;43:1-37
- Barnes PJ. Anticholinergic agents in the upper and lower airways. In: Spector SL, editor, Marcel Dekker, New York, Basel; 1999
- Ward JK, Barnes PJ, Springall DR, et al. Distribution of human i-NANC bronchodilator and nitric oxide-immunoreactive nerves. Am J respir Cell Mol Biol 1995;13:175-84
- Kummer W, Fischer A, Kurkowski R, et al. The sensory and sympathetic innervation of guinea pig lung and trachea as studied by retrograde neuronal tracing and double-labeling immunohistochemistry. Neuroscience 1988;74:265-74
- Ind PW. Airways smooth muscle: structure, innervation and neurotrasmission. In: Raeburn D, Gymbiecz M, editors, Birkhauser Verlag, Basel; 1994
- Fischer A, Hoffmann B. Nitric oxide synthase in neurons and nerve fibers of lower airways and in vagal sensory ganglia of man: correlation with neuropeptides. Am J Respir Crit Care Med 1996;154:209-16
- Cabezas GA, Graf PD, Nadel JA. Sympathetic versus parasympathetic nervous regulation of airways in dogs. J Appl Physiol 1971;31:651-5
- Diamond L, O'Donnel M. A nonadrenergic vagal inhibitory pathway to feline airways. Science 1980;208(11):185-8
- Takahashi N, Tanaka H, Abdullah N, et al. Regional difference in the distribution of L-NAME-sensitive and –insensitive NANC relaxations in cat airway. J Physiol 1995;488:709-20
- Canning BJ, Fischer A. Localization of cholinergic nerves in the airways of the guinea pig using antisera to choline acetyltransferase. Am J Physiol 1997;272:L731-8
- Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis 1986;134:1289-314
- Canning BJ, Undem BJ. Airways smooth muscle: structure, innervation and neurotrasmission. In: Raeburn D, Gymbiecz M, editors, Birkhauser Verlag, Basel; 1994
- Dixon WE, Brodie TG. Contributions to the physiology of the lungs. Part I. The bronchial muscles, their innervation, and the action of drugs upon them. J Physiol 1903;29:97-173
- Gross NJ. Antichilinergic drugs. Asthma vol. 2. Lippincott-Raven, Philadelphia, New York; 1997
- Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Curr Opin Pharmacol 2001;1:223-9
- Costello RW, Jacoby DB, Fryer AD. Pulmonary neuronal M” muscarinic receptor function in asthma and animal models of hyperreactivity. Thorax 1998;53:613-6
- Peralta EG, Ashkenazi A, Winslow JW, et al. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature 1988;334:434-7
- Berkeley JL, Levey AI. Muscarinic activation of mitogen-activated protein Kinase in PC 12 cells. J Neurochem 2000;75:487-93
- Profita M, Di GIORGI, R SALA, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005;60:1361-9
- Haddad EB, Mak JCW, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45:899-907
- Spiriva HandiHaler [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc; 2004
- Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:635-665
- Turck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004;44:163-72
- Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profilr of titotropium during long-term treatment in stable COPD [abstract]. Am J Respir Crit Care Med 1999;159:A524
- Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006;100:1925-32
- van Noord JA, Aumann JL, Janssens E, et al. Comaprison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26:214-222
- Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur respir J 1995;8:1506-13
- Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17:35-39
- McNicholas WT, Calverley PMA, Lee A, et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004;23:825-31
- Santus P, Centanni S, Morelli N, et al. Tiotropium is likely to induce oxygen desaturation in stable COPD patients compared to long-acting b2-agonists. Respir Med 2007;101:1798-803
- Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
- Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of the safety of tiotropium. Chest 2006;130:1695-1703
- Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50
- Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2008. Available from: www.fda.gov/medwatch/report.htm [Updated 7 October 2008]
- Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care-the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007;8:45
- Jara M, Lanes SF, Wentworth III C, et al. Comparative safety of long-acting inhaled bronchodilators. Drug Saf 2007;30:1151-1160
- Gross NJ. Tiotropium Bromide. Chest 2004;126:1946-53
- Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur respir J 2002;19:217-24
- Vincken W, van Noord JA, Greefhorst AP, et al. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216
- Donohuse JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55
- Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
- Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004;125:1726-34
- Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42
- Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med 2005;143:317-26
- Kario K, Uno H, Shimada K. Sleep-predominant lowering of ambulatory blood pressure by bedtime inhalation of a novel muscarinic M3 receptor antagonist: a new “Bronchoanthypertensive” strategy targeting the lung in hypertension with chronic obstructive pulmonary disease. Hypertens Res 2008;31:817-21
- Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2007;20:495-502
- Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;128:1168-78
- Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78